StockData
Curaleaf Holdings, Inc. logo

Curaleaf Holdings, Inc. (CURLF) stock analysis

CURLFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$7.63−0.20 (-2.55%)

Close on Oct 19, 2026Market cap $2.07BP/E –Yield –

StockData Score

Prices as of Nov 12, 2026How the score works

Value0Growth1Performance3Health2Dividend0

Weak6 of 30 checks passed

Curaleaf passes 6 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
3/6
Financial health
2/6
Dividend
0/6

What stands out

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 22.5% of total debt.

  • Gross margin improving

    Gross margin was 49.8% over the last twelve months, against 48.0% a year earlier.

  • Return on equity above the industry

    Curaleaf's return on equity of -26.7% is above the Drugs median of -58.0%.

  • Net margin above its 5-year average

    Net margin was -18.2% over the last twelve months, against a 5-year average of -20.3%.

What to watch

  • Return on equity under 15%

    Return on equity was -26.7% over the last twelve months and averaged -23.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 1.5%, below the 10% that usually covers the cost of capital.

  • High debt

    Debt is 70.5% of shareholders' equity, above the 40% we consider low.

  • Revenue growing under 10% a year

    Revenue grew -0.2% a year over the last three fiscal years, short of the 10% we look for.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing under 10% a year

    Revenue grew -0.2% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -5.0% over the last twelve months; the Drugs median is 7.6%.

  • Guidance issued

    The latest outlook (the year operating cash flow, Nov 3, 2026) was issued for the first time, so it neither adds nor takes away points.

  • Gross margin improving

    Gross margin was 49.8% over the last twelve months, against 48.0% a year earlier.

Past performance3/6

  • Return on equity under 15%

    Return on equity was -26.7% over the last twelve months and averaged -23.1% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 1.5%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Curaleaf's return on equity of -26.7% is above the Drugs median of -58.0%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -18.2% over the last twelve months, against a 5-year average of -20.3%.

  • Net margin above the industry

    Curaleaf's net margin of -18.2% is above the Drugs median of -53.5%.

Financial health2/6

  • High debt

    Debt is 70.5% of shareholders' equity, above the 40% we consider low.

  • Debt rising against equity

    Debt to equity rose from 21.1% five years ago to 70.5%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 22.5% of total debt.

  • Interest not well covered

    Operating income covers interest expense 0.5 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 1.52 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Curaleaf has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Curaleaf. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2018 to 2025

Gross margin

49.8%−12.6 pts over 5 years

Operating margin

2.0%−9.6 pts over 5 years

Net margin

-18.2%−9.1 pts over 5 years

See a number that looks wrong?